Fennec Pharmaceuticals Inc. (TSX:FRX)

Fennec Pharmaceuticals Revenue

Fennec Pharmaceuticals had revenue of $17.87M USD in the quarter ending June 30, 2026, with 85.18% growth. This brings the company's revenue in the last twelve months to $59.22M, up 77.83% year-over-year. In the year 2025, Fennec Pharmaceuticals had annual revenue of $44.64M, down -6.09%.

• Revenue (ttm): $59.22M
• Revenue Growth: +77.83%
• P/S Ratio: 6.26
• Revenue / Employee: $1.69M
• Employees: 35
• Market Cap: 526.88M CAD

Revenue Chart

Chart

Chart

* This company reports financials in USD.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	44.64M	-2.90M	-6.09%
Dec 31, 2024	47.54M	26.29M	123.69%
Dec 31, 2023	21.25M	19.72M	1,284.50%
Dec 31, 2022	1.54M	-	-
Dec 31, 2021	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 22, 2026

Data Sources Report a data error